Valuation : Unicycive Therapeutics, Inc.

Market Cap 141M 121M 114M 104M 195M 13.29B 196M 1.35B 525M 6.79B 528M 517M 22.32B P/E 2026 *
-4.18x
P/E 2027 * 3.13x
Enterprise Value 141M 121M 114M 104M 195M 13.29B 196M 1.35B 525M 6.79B 528M 517M 22.32B EV / Sales 2026 *
511x
EV / Sales 2027 * 0.97x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 41.2%
1 day+1.09%
1 week-5.71%
Current month-1.54%
1 month+1.29%
3 months-29.18%
6 months-26.75%
Current year-11.27%
1 week 5.04
Extreme 5.04
5.52
1 month 4.91
Extreme 4.91
5.85
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.9
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 2016-08-17
Director of Finance/CFO 64 2021-02-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 53 2016-08-17
Director/Board Member 58 2017-12-31
Director/Board Member 58 2023-09-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Free

Chief Operating Officer

169,500 0.6716%
5/14/26 Free

Executive/Senior Manager

169,500 0.6716%
5/14/26 Free

Chief Financial Officer

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%-5.71%+18.52%-32.63% 141M
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+0.33%+48.61%+89.64% 64.25B
+2.14%-0.49%-14.81%+369.42% 26.54B
+1.45%-8.14%+2.76%-15.25% 25.61B
+1.30%+0.74%+31.66%-18.33% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+2.11%+3.24%+55.78%+160.08% 14.1B
+0.93%+0.90%+24.67%+194.70% 12.45B
Average +1.19%-4.14%+43.33%+175.99% 26.32B
Weighted average by Cap. +1.28%-3.01%+42.23%+153.69%

Financials

2026 *2027 *
Net sales 275K 238K 224K 204K 381K 26.01M 384K 2.65M 1.03M 13.3M 1.03M 1.01M 43.69M 145M 125M 118M 108M 201M 13.74B 203M 1.4B 543M 7.02B 546M 534M 23.07B
Net income -34.12M -29.43M -27.73M -25.26M -47.22M -3.22B -47.57M -328M -127M -1.65B -128M -125M -5.41B 46.27M 39.91M 37.6M 34.26M 64.03M 4.37B 64.51M 445M 173M 2.23B 174M 170M 7.34B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
26-09-02 US$5.110 +1.19% 435,821
26-09-01 US$5.050 -2.88% 673,445
26-08-31 US$5.200 -1.23% 578,041
26-08-28 US$5.265 -4.27% 609,255
26-08-27 US$5.500 +1.29% 366,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.050USD
Average target price
28.22USD
Spread / Average Target
+458.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock